The esophageal cancer market landscape is poised for substantial transformation with the introduction of innovative therapeutic approaches, including antibody-drug conjugates (ADCs), next-generation targeted therapies, and combination immunotherapy regimens. Emerging candidates such as Telisotuzumab adizutecan (AbbVie) highlight this progress by delivering cytotoxic agents directly to tumor cells with greater precision.
The esophageal cancer market landscape is poised for substantial transformation with the introduction of innovative therapeutic approaches, including antibody-drug conjugates (ADCs), next-generation targeted therapies, and combination immunotherapy regimens. Emerging candidates such as Telisotuzumab adizutecan (AbbVie) highlight this progress by delivering cytotoxic agents directly to tumor cells with greater precision.